Karin Shanahan, EVP, Global Product Development and Supply at Bristol Myers Squibb joins us to discuss how she is leading one of the world’s largest manufacturing operations through rapid transformation, while integrating cutting-edge technology into BMS. Among the highlights, Karin will discuss:
- How GPS delivers value to the enterprise through the Product Development and R&D interface.
- The integration of Cell Therapy into GPS and how the company is working to improve predictability long-term.
- Establishing a competitive advantage for BMS from within GPS – an operational model built to last.
Karin will also include successful examples of GPS’s evolution to support the New Product Pipeline, most notably the recently approved Opdualag.
—
EVP, Global Product Development and Supply
Bristol-Myers Squibb
Karin Shanahan oversees worldwide product development, manufacturing and supply for Bristol Myers Squibb as executive vice president, Global Product Development & Supply (GPS). GPS develops and produces active ingredients and drug products and delivers the company’s medicines throughout the world. The GPS team achieves this mission through a relentless focus on innovation, quality, safety and agility.
“I’m excited to return to Bristol Myers Squibb, where I began my career in the pharmaceutical industry. Though I’ve worn many hats in the industry since then, I was drawn back to Bristol Myers Squibb because of its unwavering dedication to quality and delivering innovative medicines to patients in need,” says Karin. “I am honored to help lead the integral GPS team as we navigate an everchanging landscape.”
Karin began her career in the pharmaceutical industry at Bristol Myers Squibb in corporate procurement, global supply chain, and global quality. Karin moved into manufacturing operations, leading two manufacturing sites in Billerica, MA, and Latina, Italy. After almost 14 years with Bristol Myers Squibb, Karin joined Becton-Dickenson as a leader of global operations, followed by Catalent Pharmaceuticals where she led global Biologics operations. In 2013, Karin joined Teva Pharmaceuticals as senior vice president and chief operating officer of global operations, where she led global Manufacturing Science & Technology (MS&T) and Network Strategy and a network of 25 sites across Europe and the Americas. Most recently, Karin served as senior vice president of Global Biologics & Sterile Operations at Merck.
Karin earned a bachelor’s degree in political science and international relations from Rutgers University and a master’s degree in jurisprudence (MSJ), pharmaceutical and device law, from Seton Hall Law School.
